Modern Prospection for Hepatic Arterial Infusion Chemotherapy in Malignancies with Liver Metastases

Table 2

Selective studies of HAIC for liver-confined metastatic disease from colorectal cancer.

Authors/Year	Setting	Treatment	Line	Inclusion population	Patient no.; (treat)^a	Median OS; (months)	RR	Note
Kemeny et al. 2006 [41]	Pro, Ran	Arm1: HAIC → FUDR + LV + Dexa; Arm2: IV → 5-FU + LV	First line	Unresectable liver confined	68 (59); 67 (58)	24.4*; 20	47%*; 24%	QOL improvement
Fiorentini et al. 2006 [42]	Pro, phase III	Arm1: HAIC → 5-FU + LV; Arm2: HAIC → 5-FU + LV; IV → 5-FU + LV	First line	Unresectable liver confined	40 (36); 42 (40)	14; 20	41.7%; 47.5%
Fallik et al. 2003 [11]	Pro, phase II	HAIC → pirarubicin; IV → 5-FU + LV	First line	Unresectable liver confined	75 (69)	20	34.4%
Kerr et al. 2003 [43]	Pro, Ran	Arm1: HAIC → 5-FU + LV; Arm2: IV → 5-FU + LV	First line	Unresectable liver confined	145 (95); 145 (126)	14.7; 14.8	22%; 19%
Allen-Mersh et al. 2000 [44]	Pro, Ran	Arm1: HAIC → FUDR; IV → 5-FU + LV; Arm2: IV → 5-FU	First line	Unresectable liver confined	41 (39); 43 (42)	NM	45%; 23%	No QOL difference
Lorenz et al. 2000 [45]	Pro, Ran	Arm1: HAIC → 5-FU + LV; Arm2: IV → 5-FU + LV; Arm3: HAIC → FUDR	First line	Unresectable liver confined	57 (40); 57 (71)^b; 54 (37)	18.7; 17.6; 12.7	45%; 19.7%; 43.2%
Kemeny et al. 2009 [31]	Pro, phase I	HAIC → FUDR + Dexa; IV → oxaliplatin + CPT-11	First line: 23; Second line: 26	Unresectable liver confined	49 (49)	First line: 50.8; Second line: 35	92%	RCR: 47%
Ducreux et al. 2005 [37]	Pro	HAIC → Oxaliplatin; IV → 5-FU + LV	First line: 7; Second line: 21	Unresectable liver confined	28 (26)	27	64%	RCR: 18%
Kemeny et al. 2005 [46]	Pro, phase I	Arm1: HAIC → FUDR + DEXA; IV → oxaliplatin + CPT-11; Arm2: HAIC → FUDR + DEXA; IV → oxaliplatin + 5-FU + LV	First line: 4; After first line: 32	Unresectable liver confined	36 (36)	36; 22	90%; 87%
Kemeny et al. 2009 [31]	Pro, phase I	HAIC → FUDR + Dexa; IV → Oxaliplatin + CPT-11	First line: 23; Second line: 26	Unresectable liver confined	49 (49)	First line: 50.8; Second line: 35	92%	RCR: 47%
Kemeny et al. 2005 [47]	Pro, phase II	HAIC → FUDR + Dexa + Mit-C	First line: 26; Second line: 37	Unresectable liver confined	63 (63)	First line: 23; Second line: 20	First line: 73%; Second line: 70%
Lorenz et al. 2001 [48]	Pro, phase II	HAIC → 5-FU + LV	First line: 40; Second line: 10	Unresectable liver confined	50 (50)	22.3	56%
Boige et al. 2008 [38]	Pro	HAIC → oxaliplatin; IV → 5-FU + LV	After first line	Unresectable liver confined	44 (43)	16	62%	RCR: 18%
Fazio et al. 2003 [49]	Ret	HAIC → cisplatin + Mit-C + 5-FU	After first line	Hepatic mets predominent^c	45 (44)	NM	35%
Kemeny et al. 2001 [50]	Pro, phase I	HAIC → FUDR + DEXA; IV → CPT-11	After first line	Unresectable liver confined	46 (46)	17.2	74%
Van Riel et al. 2000 [51]	Ret	HAIC → 5-FU	All	Hepatic mets predominent^c	145 (145)	14.3 m	34%	Hepatic artery thrombosis (48%)
Fujimoto et al. 2009 [52]	Ret	HAIC → 5-FU	NM	Unresectable liver confined	72 (72)	18	38%
Sameshima et al. 2007 [53]	Ret	HAIC → 5-FU	NM	Unresectable liver confined	42 (42)	29.1	57%

Selected studies that enroll patients with colorectal cancer-related liver-confined metastatic disease are listed here. Studies designed for patients with colorectal cancer to receive systemic chemotherapy in combination with HAIC are listed in Table 1.
∗With statistical significance.
^aActual patients’ number who received treatment.
^bPatients who did not receive treatment in arm1 and arm3 received treatment as arm2.
^cTrial enrolled patients with liver-confined disease or “minimal” extrahepatic disease.
Abbreviations—OS: overall survival, RR: response rate, Pro: prospective, Ran: randomized, Ret: retrospective, NM: not mentioned, HAIC: hepatic artery infusion chemotherapy, IV: intravenous, FUDR: floxuridine, LV: leucovorin, Dexa: dexamethasone, Mit-C: mitomycin C, CPT-11: irinotecan, QOL: quality of life, Mets: metastasis, and RCR: resectability conversion rate.